Vivoryon Therapeutics N.V. buy melinda
Start price
26.11.17
/
50%
€11.80
Target price
16.01.18
€17.00
Performance (%)
23.74%
End price
16.01.18
€14.60
Summary
This prediction ended on 16.01.18 with a price of €14.60. The prediction had a final performance of 23.74%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vivoryon Therapeutics N.V. | 28.899% | 28.899% | -4.161% | -88.272% |
| iShares Core DAX® | -2.680% | 4.261% | 2.121% | 57.510% |
| iShares Nasdaq 100 | 0.725% | 5.796% | 34.204% | 92.829% |
| iShares Nikkei 225® | -0.725% | 9.319% | 61.298% | 80.340% |
| iShares S&P 500 | 1.166% | 5.479% | 24.751% | 70.967% |
According to melinda what are the pros and cons of Vivoryon Therapeutics N.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Vivoryon Therapeutics AG diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 27/11 | 02.00 Präsentation
Probiodrug ist auf die Erforschung und Entwicklung von therapeutischen Produkten für die Behandlung der Alzheimer-Krankheit. Am Ende 2016 hat die Gruppe einen Portfolio von Produkten 2 in der vorklinischen Entwicklung (PBD-C06 und PQ1565) und ein Produkt in der Phase IIa
(Vom Mitglied beendet)
Stopped prediction by melinda for Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€18.36
27.11.21
27.11.21
€19.00
27.11.22
27.11.22
-50.44%
28.11.22
28.11.22
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€3.80
16.03.20
16.03.20
€5.00
04.11.21
04.11.21
437.55%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€5.48
26.02.20
26.02.20
€7.50
16.03.20
16.03.20
-30.75%
16.03.20
16.03.20
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€11.80
26.11.17
26.11.17
€17.00
16.01.18
16.01.18
23.74%
16.01.18
16.01.18
Could be worthwhile Investment >10% per year


